title: Clinical applications of filgrastim and stem cell factor in vivo and in vitro.
authors.affiliation: Amgen, Inc., Thousand Oaks, California, USA.
authors.forename: G
authors.initials: G
authors.lastname: Morstyn
authors.forename: J
authors.initials: J
authors.lastname: Glaspy
authors.forename: E J
authors.initials: EJ
authors.lastname: Shpall
authors.forename: F
authors.initials: F
authors.lastname: LeMaistre
authors.forename: R
authors.initials: R
authors.lastname: Briddell
authors.forename: D
authors.initials: D
authors.lastname: Menchaca
authors.forename: M
authors.initials: M
authors.lastname: Lill
authors.forename: R B
authors.initials: RB
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Tami
authors.forename: S
authors.initials: S
authors.lastname: Brown
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D019089:Stem Cell Factor
chemical_list: D016298:Hematopoietic Cell Growth Factors; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim